1 / 9

Changes in Serum Proteome Linked to Lung Cancer and Their Reversal Post Tumor Resection

This study investigates the alterations in the serum proteome associated with lung cancer and examines how these changes are reversed after tumor resection. Utilizing advanced techniques such as ImmunoSELDI and MS/MS spectrometry, we identify key proteins, including Apolipoprotein C1, Lysozyme C, and Transthyretin, and provide a detailed analysis of their respective spectra. Our findings contribute to the understanding of lung cancer biomarkers and the potential for using serum protein profiles in monitoring treatment outcomes after surgery.

sadah
Download Presentation

Changes in Serum Proteome Linked to Lung Cancer and Their Reversal Post Tumor Resection

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Supplemental Data Rathinam et al: Changes in the serum proteome associated with lung cancer and their reversal following tumor resection Table S1: Patient Information. Fig A: Apolipoprotein C1 ImmunoSELDI. The experiment was performed as descibed in reference 7. The antibody used was a mouse monoclonal to human apolipoprotein C1 purchased from Chemicon International Inc (MAB1064). Fig B: Lsozyme C ImmunoSELDI. The antibody used was a rabbit polyclonal to human lysozyme C purchased from Abcam (ab2408) Figs C & D: MS/MS spectra used to identify Lysozyme Fig E-I: MS/MS spectra used to identify Transthyretin Fig J: Transthyretin ImmunoSELDI. The antibody used was a rabbit polyclonal to human transthyretin purchased from from Abcam (ab16006). Figs K & L: MS/MS spectra used to identify th4 m/z 5080 fragment of transthyretin. Fig M: Accurate mass determination of the m/z 5080 fragment of transthyretin. Fig N: M/Z 5080 ImmunoSELDI. The same antibody was used as in the intact transthyretin ImmunoSELDI (Fig J). Fig O: MS/MS spectra used to identify the m/z 3273 and 3289 fragments of ITIH4. The top spectrum/peptide is common to both fragments and the annotated spectra below show both the oxidised and non-oxidised verions of the methioinine containing peptide.

  2. Fig A 13000 14000 15000 16000 Lysozyme C ImmunoSELDI Fig B A Whole serum * B Depleted serum Intensity C Eluted proteins * 13000 14000 15000 16000 m/z

  3. Lysozyme MS/MS Fig C R.STDYGIFQINSR.Y R.GISLALWMC*LAK.W * = carboxyamidomethylation Fig D

  4. Transthyretin MS/MS Fig E K.TSESGELHGLTTEEEFVEGIYK.V Fig F R.GSPAINVAVHVFR.K

  5. Fig G K.AADDTWEPFASGK.T Fig H R.KAADDTWEPFASGK.T

  6. Fig I K.ALGISPFHEHAEVVFTANDSGPR.R Transthyretin ImmunoSELDI Fig J Whole serum A Depleted serum Intensity B Eluted proteins C 13000 14000 15000 m/z

  7. ‘5080’ MS/MS Fig K K.ALGISPFHEHAEVVFTANDSGPR.R Fig L A.ALLSPYSYSTTAVVTNPK.E

  8. m/z 5080(Transthyretin Fragment) ImmunoSELDI Whole serum M1 Intensity Depleted serum Eluted proteins * M2 m/z Fig M Fig N

  9. ‘3273/3289’ MS/MS MNFRPGVLSSR y1-4 b1-2 y1-3 b1-7 y1-7 b1-4 y1-2 y1-6 M*NFRPGVLSSR y1-7 y1-3 y1-4 b1-4 b1-2 b1-7 y1-6 R.PGVLSSRQLGLPGPPDVPDHAAYHPF.R (common to both) Fig O

More Related